Hims & Hers Health Analysts Cut Their Forecasts After Q4 Results

Benzinga01:46

Hims & Hers Health Inc (NYSE:HIMS) reported mixed financial results for the fourth quarter after the market close on Monday.

Hims & Hers Health reported fourth-quarter revenue of $617.82 million, missing analyst estimates of $619.22 million. The company reported fourth-quarter earnings of eight cents per share, beating estimates of three cents per share, according to Benzinga Pro.

"More than 2.5 million subscribers now rely on us for a health care experience that is both accessible and deeply personal — and we believe we're well on our way to becoming the global leader in consumer health," said Andrew Dudum, co-founder and CEO of Hims & Hers Health.

Hims & Hers Health expects first-quarter revenue of $600 million to $625 million versus estimates of $653.12 million. The company also guided for full-year 2026 revenue of $2.7 billion to $2.9 billion versus estimates of $2.74 billion.

Hims & Hers Health shares fell 0.1% to trade at $15.53 on Tuesday.

These analysts made changes to their price targets on Hims & Hers Health following earnings announcement.

Evercore ISI Group analyst Mark Mahaney maintained Hims & Hers Health with an In-Line rating and lowered the price target from $33 to $24.
Truist Securities analyst Jailendra Singh reiterated the stock with a Hold and cut the price target from $37 to $18.
TD Cowen analyst Jonna Kim maintained the stock with a Hold and lowered the price target from $20 to $17.
Citigroup analyst Daniel Grosslight maintained Hims & Hers Health with a Sell and lowered the price target from $16.5 to $13.25.

Considering buying HIMS stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614329741?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 01:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614329741","market":"us","top_or_hot":-1,"title":"Hims & Hers Health Analysts Cut Their Forecasts After Q4 Results","media":"Benzinga","content":"<html><body><p><strong>Hims &amp; Hers Health Inc </strong>(NYSE:HIMS) reported mixed financial results for the fourth quarter after the market close on Monday.</p>\n<p>Hims &amp; Hers Health reported fourth-quarter revenue of $617.82 million, missing analyst estimates of $619.22 million. The company reported fourth-quarter earnings of eight cents per share, beating estimates of three cents per share, according to Benzinga Pro.</p>\n<p>\"More than 2.5 million subscribers now rely on us for a health care experience that is both accessible and deeply personal — and we believe we're well on our way to becoming the global leader in consumer health,\" said Andrew Dudum, co-founder and CEO of Hims &amp; Hers Health.</p>\n<p>Hims &amp; Hers Health expects first-quarter revenue of $600 million to $625 million versus estimates of $653.12 million. The company also guided for full-year 2026 revenue of $2.7 billion to $2.9 billion versus estimates of $2.74 billion.</p>\n<p>Hims &amp; Hers Health shares fell 0.1% to trade at $15.53 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Hims &amp; Hers Health following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI Group analyst Mark Mahaney maintained Hims &amp; Hers Health with an In-Line rating and lowered the price target from $33 to $24.</li>\n<li>Truist Securities analyst Jailendra Singh reiterated the stock with a Hold and cut the price target from $37 to $18.</li>\n<li>TD Cowen analyst Jonna Kim maintained the stock with a Hold and lowered the price target from $20 to $17.</li>\n<li>Citigroup analyst Daniel Grosslight maintained Hims &amp; Hers Health with a Sell and lowered the price target from $16.5 to $13.25.</li>\n</ul>\n<p><strong>Considering buying HIMS stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"507\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-1024x507.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-1024x507.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-768x380.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572.png 1203w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Health Analysts Cut Their Forecasts After Q4 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Health Analysts Cut Their Forecasts After Q4 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-02-25 01:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>Hims &amp; Hers Health Inc </strong>(NYSE:HIMS) reported mixed financial results for the fourth quarter after the market close on Monday.</p>\n<p>Hims &amp; Hers Health reported fourth-quarter revenue of $617.82 million, missing analyst estimates of $619.22 million. The company reported fourth-quarter earnings of eight cents per share, beating estimates of three cents per share, according to Benzinga Pro.</p>\n<p>\"More than 2.5 million subscribers now rely on us for a health care experience that is both accessible and deeply personal — and we believe we're well on our way to becoming the global leader in consumer health,\" said Andrew Dudum, co-founder and CEO of Hims &amp; Hers Health.</p>\n<p>Hims &amp; Hers Health expects first-quarter revenue of $600 million to $625 million versus estimates of $653.12 million. The company also guided for full-year 2026 revenue of $2.7 billion to $2.9 billion versus estimates of $2.74 billion.</p>\n<p>Hims &amp; Hers Health shares fell 0.1% to trade at $15.53 on Tuesday.</p>\n<p>These analysts made changes to their price targets on Hims &amp; Hers Health following earnings announcement.</p>\n<ul>\n<li><a href=\"https://laohu8.com/S/EVR\">Evercore</a> ISI Group analyst Mark Mahaney maintained Hims &amp; Hers Health with an In-Line rating and lowered the price target from $33 to $24.</li>\n<li>Truist Securities analyst Jailendra Singh reiterated the stock with a Hold and cut the price target from $37 to $18.</li>\n<li>TD Cowen analyst Jonna Kim maintained the stock with a Hold and lowered the price target from $20 to $17.</li>\n<li>Citigroup analyst Daniel Grosslight maintained Hims &amp; Hers Health with a Sell and lowered the price target from $16.5 to $13.25.</li>\n</ul>\n<p><strong>Considering buying HIMS stock? Here’s what analysts think:</strong> </p>\n<figure><img decoding=\"async\" height=\"507\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-1024x507.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-1024x507.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572-768x380.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/02/24124450/image-572.png 1203w\" width=\"1024\"/></figure>\n<p>Photo via Shutterstock</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50825141/hims-hers-health-analysts-cut-their-forecasts-after-q4-results","article_id":"2614329741","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614329741","pubTimestamp":1771955163,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":" ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","HIMY":"Defiance Leveraged Long + Income HIMS ETF","HIMS":"Hims & Hers Health Inc.","HMYY":"GraniteShares YieldBoost HIMS ETF","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","HIYY":"YieldMax HIMS Option Income Strategy ETF"},"translate_title":"Hims&Hers Health分析师在第四季度业绩公布后下调了预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HMYY":0.6,"HIMY":0.6,"HIYY":0.6,"HIMS":1.98,"HIMZ":0.6},"content_text":"Hims & Hers Health Inc (NYSE:HIMS) reported mixed financial results for the fourth quarter after the market close on Monday.\nHims & Hers Health reported fourth-quarter revenue of $617.82 million, missing analyst estimates of $619.22 million. The company reported fourth-quarter earnings of eight cents per share, beating estimates of three cents per share, according to Benzinga Pro.\n\"More than 2.5 million subscribers now rely on us for a health care experience that is both accessible and deeply personal — and we believe we're well on our way to becoming the global leader in consumer health,\" said Andrew Dudum, co-founder and CEO of Hims & Hers Health.\nHims & Hers Health expects first-quarter revenue of $600 million to $625 million versus estimates of $653.12 million. The company also guided for full-year 2026 revenue of $2.7 billion to $2.9 billion versus estimates of $2.74 billion.\nHims & Hers Health shares fell 0.1% to trade at $15.53 on Tuesday.\nThese analysts made changes to their price targets on Hims & Hers Health following earnings announcement.\n\nEvercore ISI Group analyst Mark Mahaney maintained Hims & Hers Health with an In-Line rating and lowered the price target from $33 to $24.\nTruist Securities analyst Jailendra Singh reiterated the stock with a Hold and cut the price target from $37 to $18.\nTD Cowen analyst Jonna Kim maintained the stock with a Hold and lowered the price target from $20 to $17.\nCitigroup analyst Daniel Grosslight maintained Hims & Hers Health with a Sell and lowered the price target from $16.5 to $13.25.\n\nConsidering buying HIMS stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614329741","isCrawlerRequest":true}